Pancreatic Cancer Research

ResearcherCentro di Riferimento OncologicoActive in the last 2 years

Michele Dal Bo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8668-7621; OpenAlex author ID A5028533961. Sources: OpenAlex.

Their work

Papers
4 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
6
Papers, trials and grants by year

2022: 1 paper · 2023: 1 paper · 2024: none · 2025: none · 2026: 2 papers

Papers 4

  1. The anti-GPC1 antibody AT101 as effective targeting agent for chemotherapeutic-loaded chitosan nanobubbles in the treatment of pancreatic adenocarcinoma. Last author DOI 10.1016/j.biopha.2026.119956↗
  2. PLGA/PVA nanoparticles to deliver a protein-based cancer vaccine targeting GPC1 for the treatment of pancreatic ductal adenocarcinoma. Last author DOI 10.1080/17435889.2026.2676617↗
  3. A novel complement-fixing IgM antibody targeting GPC1 as a useful immunotherapeutic strategy for the treatment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12967-023-04745-9↗
  4. The Proteoglycan Glypican-1 as a Possible Candidate for Innovative Targeted Therapeutic Strategies for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/ijms231810279↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Davide Busato · 4 shared papers, 2022–2026 · strength 0.93
  2. Giuseppe Toffoli · 4 shared papers, 2022–2026 · strength 0.93
  3. Amin Safa · 1 shared paper, 2026 · strength 0.30
  4. Idris Vruzhaj · 1 shared paper, 2026 · strength 0.30
  5. Marta Gambirasi · 1 shared paper, 2026 · strength 0.30
  6. Monica Argenziano · 1 shared paper, 2026 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.